Table 4.
Values of serum lipids, fasting glucose, and uric acid
| Parameter | Whole sample (N = 36) |
Subsample (N = 18) |
||||
|---|---|---|---|---|---|---|
| Baseline | End phase 1 | Mean difference (95% CI) | End phase 1 | End phase 2 | Mean difference (95% CI) | |
| Cholesterol (mmol/L) | 4.9 ± 1.2 | 4.1 ± 0.8*** | 0.7 (0.4–1) | 4.2 ± 0.8 | 4.2 ± 0.8 | –0.04 (−0.3 to 0.2) |
| LDL-cholesterol (mmol/L) | 3.2 ± 1 | 2.6 ± 0.7*** | 0.6 (0.3–0.8) | 2.6 ± 0.6 | 2.6 ± 0.7 | 0 (−0.2 to 0.2) |
| HDL-cholesterol (mmol/L) | 1.3 ± 0.3 | 1.2 ± 0.3*** | 0.16 (0.1–0.2) | 1.2 ± 0.3 | 1.2 ± 0.3 | 0 (−0.1 to 0.05) |
| Triglycerides (mmol/L) | 1.3 ± 0.8 | 1.2 ± 0.6 | 0 (−0.2–0.2) | 1.3 ± 0.7 | 1.3 ± 0.6 | 0 (−0.1 to 0.2) |
| Non-HDL-cholesterol (mmol/L) | 3.5 ± 1.2 | 2.9 ± 0.8*** | 0.6 (0.3–0.9) | 3 ± 0.7 | 3 ± 0.7 | 0 (−0.3 to 0.3) |
| Fasting glucose (mmol/L) | 5.2 (4.2–9.9) | 5 (4.3–7.1)† | N.A. | 5.1 (4.6–7.1) | 5.1 (4.4–6.7) | NA |
| Uric acid (μmol/L) | 318 ± 78 | 332 ± 79* | 15 (1–28) | 330 ± 77 | 321 ± 86 | −9 (−33 to 15) |
CI, confidence interval for the difference between study time points;
*
P < 0.05 compared with the previous study time point;
***
P < 0.001 compared with the previous study time point; NA, 95% CI for differences were not calculated due to a non-normal distribution of data.
†
Reduction of fasting glucose in phase 1 did not reach statistical significance with a P of 0.08. Data are shown as mean ± standard deviation for normally distributed variables and as median (minimum–maximum) for non-normally distributed ones.